JAK2 and Splenomegaly: 74‐year‐old male, JAK2‐positive post‐ET MF with splenomegalyRuxolitinib monotherapySpleen response but transfusion‐dependent anaemiaSubsequent loss of response (splenomegaly, symptoms and leucocytosis)Ruxolitinib and navitoclax via REFINE (NCT03222609)Progressive splenomegaly and leucocytosisRuxolitinib and hydroxycarbamideDecreased spleen size and symptomsLeucocytosis and thrombocytopeniaDied